Randomized double-blind study of prophylactic methenamine hippurate treatment of patients with indwelling catheters.

Abstract

Catheterized patients with heavy bacteriuria and short catheter life received a short-course of antimicrobial therapy and then were allocated at random to double-blind treatment for 5 months with methenamine hippurate (MH), 1 g three times daily, or placebo 1 g 3 times daily. MH treatment reduced the number of catheter blockages and instances of spontaneous removal of the catheter, and doubled catheter life (p less than 0.001). It is suggested that the doubled catheter life was due to the reduced bacteriuria and lowering of urinary pH.

• Authors: A Norberg, B Norberg, U Parkhede, H Gippert, K Lundbeck
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 18 Issue 6 Pg. 497-500 (Nov 1980) ISSN: 0031-6970 [Print] Germany
• PMID: 7007058 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Hippurates
• Methenamine
• methenamine hippurate

Topics

• Aged
• Anti-Bacterial Agents (therapeutic use)
• Bacteriuria (complications, drug therapy)
• Catheters, Indwelling
• Clinical Trials as Topic
• Dementia (complications)
• Double-Blind Method
• Female
• Hippurates (therapeutic use)
• Humans
• Male
• Methenamine (analogs & derivatives, therapeutic use)
• Time Factors
• Urinary Catheterization
• Urinary Incontinence (complications, therapy)